Chemical-structure (Sumatriptan Succinate 25mg 1)
Sumatriptan Succinate
Product Images NDC 33261-662
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sumatriptan Succinate (NDC 33261-662). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Sumatriptan-figure-1 (Sumatriptan Succinate 25mg 2)
This figure displays the estimated probability of achieving initial headache relief within 4 hours of treatment using oral sumatriptan. The chart shows the probability of response over time and includes different doses of medication, including placebo. The data is based on pooled information from 3 clinical trials and is presented using a Kaplan-Meier plot with censoring at 240 minutes for patients who did not respond or needed additional treatment.*
Sumatriptan-figure-2 (Sumatriptan Succinate 25mg 3)
The text is describing a figure showing the estimated probability of patients taking a second dose of Sumatriptan Succinate Tablets or other medication to treat migraine within 24 hours after the initial dose. The figure includes data from three controlled trials and shows the probability based on the dosage and time elapsed since the initial dose. No remedication was allowed within 2 hours postdose.*
33261-0662_sumatriptan-succ_25mg (Sumatriptan Succinate 25mg 4)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
